Literature DB >> 31328434

Bioinspired Liposomes for Oral Delivery of Colistin to Combat Intracellular Infections by Salmonella enterica.

Sara Menina1,2, Janina Eisenbeis3, Mohamed Ashraf M Kamal1, Marcus Koch4, Markus Bischoff3, Sarah Gordon1,5, Brigitta Loretz1, Claus-Michael Lehr1,2.   

Abstract

Bacterial invasion into eukaryotic cells and the establishment of intracellular infection has proven to be an effective means of resisting antibiotic action, as anti-infective agents commonly exhibit a poor permeability across the host cell membrane. Encapsulation of anti-infectives into nanoscaled delivery systems, such as liposomes, is shown to result in an enhancement of intracellular delivery. The aim of the current work is, therefore, to formulate colistin, a poorly permeable anti-infective, into liposomes suitable for oral delivery, and to functionalize these carriers with a bacteria-derived invasive moiety to enhance their intracellular delivery. Different combinations of phospholipids and cholesterol are explored to optimize liposomal drug encapsulation and stability in biorelevant media. These liposomes are then surface-functionalized with extracellular adherence protein (Eap), derived from Staphylococcus aureus. Treatment of HEp-2 and Caco-2 cells infected with Salmonella enterica using colistin-containing, Eap-functionalized liposomes resulted in a significant reduction of intracellular bacteria, in comparison to treatment with nonfunctionalized liposomes as well as colistin alone. This indicates that such bio-invasive carriers are able to facilitate intracellular delivery of colistin, as necessary for intracellular anti-infective activity. The developed Eap-functionalized liposomes, therefore, present a promising strategy for improving the therapy of intracellular infections.
© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Eap; Staphylococcus aureuszzm321990; bacterial invasion; bacteriomimetic nanocarriers; extracellular adherence proteins; simulated intestinal fluids

Year:  2019        PMID: 31328434     DOI: 10.1002/adhm.201900564

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  6 in total

1.  Nanoparticle-Enabled Combination Therapy Showed Superior Activity against Multi-Drug Resistant Bacterial Pathogens in Comparison to Free Drugs.

Authors:  Amarpreet Brar; Satwik Majumder; Maria Zardon Navarro; Marie-Odile Benoit-Biancamano; Jennifer Ronholm; Saji George
Journal:  Nanomaterials (Basel)       Date:  2022-06-24       Impact factor: 5.719

Review 2.  Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections.

Authors:  Jessa Marie V Makabenta; Ahmed Nabawy; Cheng-Hsuan Li; Suzannah Schmidt-Malan; Robin Patel; Vincent M Rotello
Journal:  Nat Rev Microbiol       Date:  2020-08-19       Impact factor: 60.633

Review 3.  Polymyxin Delivery Systems: Recent Advances and Challenges.

Authors:  Natallia V Dubashynskaya; Yury A Skorik
Journal:  Pharmaceuticals (Basel)       Date:  2020-04-29

4.  Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7).

Authors:  Amir Shakouri; Houman Kahroba; Hamed Hamishekar; Jalal Abdolalizadeh
Journal:  Bioimpacts       Date:  2021-08-09

5.  Myxobacteria-Derived Outer Membrane Vesicles: Potential Applicability Against Intracellular Infections.

Authors:  Adriely Goes; Philipp Lapuhs; Thomas Kuhn; Eilien Schulz; Robert Richter; Fabian Panter; Charlotte Dahlem; Marcus Koch; Ronald Garcia; Alexandra K Kiemer; Rolf Müller; Gregor Fuhrmann
Journal:  Cells       Date:  2020-01-12       Impact factor: 6.600

6.  Synthesis and Biopharmaceutical Characterization of Amphiphilic Squalenyl Derivative Based Versatile Drug Delivery Platform.

Authors:  Duy-Khiet Ho; Rebekka Christmann; Xabier Murgia; Chiara De Rossi; Sarah Frisch; Marcus Koch; Ulrich F Schaefer; Brigitta Loretz; Didier Desmaele; Patrick Couvreur; Claus-Michael Lehr
Journal:  Front Chem       Date:  2020-10-19       Impact factor: 5.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.